Trade Day One Biopharmaceuticals - DAWN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.09 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Day One Biopharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 11.6 |
Open* | 11.57 |
1-Year Change* | -45.78% |
Day's Range* | 11.43 - 11.57 |
52 wk Range | 9.67-25.77 |
Average Volume (10 days) | 558.59K |
Average Volume (3 months) | 17.95M |
Market Cap | 1.04B |
P/E Ratio | -100.00K |
Shares Outstanding | 87.04M |
Revenue | N/A |
EPS | -2.30 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 27, 2023 | 11.60 | -0.28 | -2.36% | 11.88 | 11.96 | 11.42 |
Nov 24, 2023 | 12.01 | 0.45 | 3.89% | 11.56 | 12.25 | 11.54 |
Nov 22, 2023 | 11.82 | 0.00 | 0.00% | 11.82 | 12.09 | 11.77 |
Nov 21, 2023 | 11.89 | 0.31 | 2.68% | 11.58 | 12.12 | 11.41 |
Nov 20, 2023 | 12.09 | 0.03 | 0.25% | 12.06 | 12.39 | 11.96 |
Nov 17, 2023 | 12.11 | 0.68 | 5.95% | 11.43 | 12.24 | 11.42 |
Nov 16, 2023 | 11.67 | -0.05 | -0.43% | 11.72 | 11.97 | 11.35 |
Nov 15, 2023 | 12.04 | 0.06 | 0.50% | 11.98 | 12.42 | 11.94 |
Nov 14, 2023 | 12.13 | 0.66 | 5.75% | 11.47 | 12.16 | 11.47 |
Nov 13, 2023 | 11.36 | 0.48 | 4.41% | 10.88 | 11.41 | 10.81 |
Nov 10, 2023 | 11.30 | 0.17 | 1.53% | 11.13 | 11.37 | 10.85 |
Nov 9, 2023 | 11.18 | -0.70 | -5.89% | 11.88 | 11.99 | 11.13 |
Nov 8, 2023 | 12.11 | 0.00 | 0.00% | 12.11 | 12.54 | 11.88 |
Nov 7, 2023 | 12.31 | 0.28 | 2.33% | 12.03 | 12.72 | 11.79 |
Nov 6, 2023 | 12.15 | -0.57 | -4.48% | 12.72 | 12.87 | 12.11 |
Nov 3, 2023 | 12.70 | 0.63 | 5.22% | 12.07 | 12.84 | 12.06 |
Nov 2, 2023 | 11.99 | 0.31 | 2.65% | 11.68 | 12.06 | 11.65 |
Nov 1, 2023 | 11.81 | 0.34 | 2.96% | 11.47 | 12.00 | 11.43 |
Oct 31, 2023 | 11.79 | 0.16 | 1.38% | 11.63 | 12.01 | 11.47 |
Oct 30, 2023 | 11.85 | 0.82 | 7.43% | 11.03 | 12.49 | 10.97 |
Day One Biopharmaceuticals Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 |
Total Operating Expense | 146.909 | 72.743 | 13.782 | 14.905 |
Selling/General/Admin. Expenses, Total | 61.291 | 29.159 | 4.682 | 1.006 |
Research & Development | 85.618 | 43.584 | 9.1 | 13.899 |
Operating Income | -146.909 | -72.743 | -13.782 | -14.905 |
Interest Income (Expense), Net Non-Operating | 4.746 | 0.004 | -30.03 | -2.077 |
Other, Net | -0.018 | -0.015 | -0.031 | -0.002 |
Net Income Before Taxes | -142.181 | -72.754 | -43.843 | -16.984 |
Net Income After Taxes | -142.181 | -72.754 | -43.843 | -16.984 |
Minority Interest | 0 | -97.885 | 3.336 | 4.35 |
Net Income Before Extra. Items | -142.181 | -170.639 | -40.507 | -12.634 |
Net Income | -142.181 | -170.639 | -40.507 | -12.634 |
Income Available to Common Excl. Extra. Items | -142.181 | -170.639 | -40.507 | -12.634 |
Income Available to Common Incl. Extra. Items | -142.181 | -170.639 | -40.507 | -12.634 |
Diluted Net Income | -142.181 | -170.639 | -40.507 | -12.634 |
Diluted Weighted Average Shares | 65.4668 | 36.9606 | 60.3374 | 60.3374 |
Diluted EPS Excluding Extraordinary Items | -2.1718 | -4.61678 | -0.67134 | -0.20939 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
Diluted Normalized EPS | -2.1718 | -4.61678 | -0.67134 | -0.20939 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 49.254 | 45.855 | 42.743 | 39.699 | 36.719 |
Selling/General/Admin. Expenses, Total | 17.072 | 18.027 | 16.723 | 17.664 | 14.159 |
Research & Development | 32.182 | 27.828 | 26.02 | 22.035 | 22.56 |
Operating Income | -49.254 | -45.855 | -42.743 | -39.699 | -36.719 |
Interest Income (Expense), Net Non-Operating | 3.406 | 3.466 | 2.66 | 1.895 | 0.189 |
Other, Net | -0.015 | -0.004 | -0.026 | 0.009 | 0 |
Net Income Before Taxes | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
Net Income After Taxes | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
Minority Interest | 0 | 0 | 0 | ||
Net Income Before Extra. Items | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
Net Income | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
Income Available to Common Excl. Extra. Items | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
Income Available to Common Incl. Extra. Items | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
Diluted Net Income | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
Diluted Weighted Average Shares | 74.9649 | 71.9729 | 71.2988 | 71.009 | 60.7605 |
Diluted EPS Excluding Extraordinary Items | -0.61179 | -0.58901 | -0.56255 | -0.53226 | -0.60121 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.61179 | -0.58901 | -0.56255 | -0.53226 | -0.60121 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total Current Assets | 347.874 | 289.368 | 45.071 | 27.339 |
Cash and Short Term Investments | 342.269 | 284.309 | 43.728 | 27.332 |
Cash | 85.262 | 284.309 | 43.728 | 27.332 |
Prepaid Expenses | 5.605 | 5.059 | 1.343 | 0.007 |
Total Assets | 349.062 | 289.821 | 45.661 | 27.339 |
Total Current Liabilities | 16.615 | 8.657 | 1.996 | 2.021 |
Accounts Payable | 0.26 | 1.744 | 0.202 | 0.069 |
Accrued Expenses | 16.176 | 6.809 | 1.767 | 0.466 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.179 | 0.104 | 0.027 | 1.486 |
Total Liabilities | 17.023 | 8.673 | 7.902 | 7.508 |
Total Long Term Debt | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 5.702 | 5.487 | |
Other Liabilities, Total | 0.408 | 0.016 | 0.204 | 0 |
Total Equity | 332.039 | 281.148 | 37.759 | 19.831 |
Redeemable Preferred Stock | 0 | 91.964 | 30.504 | |
Common Stock | 0.007 | 0.006 | 2.637 | 2.111 |
Retained Earnings (Accumulated Deficit) | -269.668 | -127.487 | -56.842 | -12.784 |
Total Liabilities & Shareholders’ Equity | 349.062 | 289.821 | 45.661 | 27.339 |
Total Common Shares Outstanding | 73.4582 | 61.9523 | 60.3374 | 60.3374 |
Property/Plant/Equipment, Total - Net | 0.719 | 0.284 | 0.483 | |
Property/Plant/Equipment, Total - Gross | 0.725 | 0.32 | 0.499 | |
Accumulated Depreciation, Total | -0.006 | -0.036 | -0.016 | |
Long Term Investments | 0.469 | 0.169 | 0.107 | |
Additional Paid-In Capital | 601.771 | 408.629 | ||
Short Term Investments | 257.007 | |||
Other Equity, Total | -0.071 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 413.291 | 449.784 | 322.388 | 347.874 | 380.513 |
Cash and Short Term Investments | 405.538 | 442.882 | 318.179 | 342.269 | 374.341 |
Cash | 241.179 | 189.211 | 49.268 | 85.262 | 120.864 |
Prepaid Expenses | 7.753 | 6.902 | 4.209 | 5.605 | 6.172 |
Total Assets | 414.179 | 450.756 | 323.563 | 349.062 | 381.861 |
Property/Plant/Equipment, Total - Net | 0.655 | 0.713 | 0.688 | 0.719 | 0.899 |
Property/Plant/Equipment, Total - Gross | 0.685 | 0.731 | 0.7 | 0.725 | 0.982 |
Accumulated Depreciation, Total | -0.03 | -0.018 | -0.012 | -0.006 | -0.083 |
Long Term Investments | 0.233 | 0.259 | 0.487 | 0.469 | 0.449 |
Total Current Liabilities | 24.475 | 24.512 | 22.848 | 16.615 | 18.271 |
Accounts Payable | 3.391 | 4.565 | 4.657 | 0.26 | 3.973 |
Accrued Expenses | 20.675 | 19.761 | 17.676 | 16.176 | 13.845 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.409 | 0.186 | 0.515 | 0.179 | 0.453 |
Total Liabilities | 24.552 | 24.702 | 23.148 | 17.023 | 18.785 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Minority Interest | |||||
Other Liabilities, Total | 0.077 | 0.19 | 0.3 | 0.408 | 0.514 |
Total Equity | 389.627 | 426.054 | 300.415 | 332.039 | 363.076 |
Redeemable Preferred Stock | |||||
Common Stock | 0.009 | 0.009 | 0.007 | 0.007 | 0.007 |
Retained Earnings (Accumulated Deficit) | -404.074 | -357.924 | -312.061 | -269.668 | -229.559 |
Total Liabilities & Shareholders’ Equity | 414.179 | 450.756 | 323.563 | 349.062 | 381.861 |
Total Common Shares Outstanding | 87.0429 | 86.9713 | 73.5726 | 73.4582 | 73.5119 |
Additional Paid-In Capital | 793.699 | 783.978 | 612.402 | 601.771 | 593.02 |
Short Term Investments | 164.359 | 253.671 | 268.911 | 257.007 | 253.477 |
Other Equity, Total | -0.007 | -0.009 | 0.067 | -0.071 | -0.392 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Net income/Starting Line | -142.181 | -72.754 | -43.843 | -16.984 |
Cash From Operating Activities | -109.874 | -48.539 | -13.489 | -4.515 |
Cash From Operating Activities | 0.063 | 0.02 | 0.016 | 0 |
Non-Cash Items | 25.68 | 21.5 | 30.695 | 12.025 |
Changes in Working Capital | 6.564 | 2.695 | -0.357 | 0.444 |
Cash From Investing Activities | -255.074 | -8 | -0.092 | 0 |
Capital Expenditures | -0.026 | 0 | -0.092 | 0 |
Cash From Financing Activities | 165.901 | 297.12 | 29.977 | 30.905 |
Financing Cash Flow Items | 0 | 0 | 1 | |
Issuance (Retirement) of Stock, Net | 165.901 | 297.12 | 29.977 | 29.905 |
Net Change in Cash | -199.047 | 240.581 | 16.396 | 26.39 |
Other Investing Cash Flow Items, Total | -255.048 | -8 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -42.393 | -142.181 | -102.072 | -64.277 | -27.747 |
Cash From Operating Activities | -25.985 | -109.874 | -74.564 | -51.35 | -21.563 |
Cash From Operating Activities | 0.006 | 0.063 | 0.048 | 0.012 | 0.006 |
Non-Cash Items | 8.931 | 25.68 | 19.681 | 12.007 | 6.249 |
Changes in Working Capital | 7.471 | 6.564 | 7.779 | 0.908 | -0.071 |
Cash From Investing Activities | -11.193 | -255.074 | -252.864 | -6.012 | -0.015 |
Other Investing Cash Flow Items, Total | -11.167 | -255.048 | -252.838 | -5.99 | 0 |
Cash From Financing Activities | 1.184 | 165.901 | 163.983 | 161.93 | 0 |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Stock, Net | 1.184 | 165.901 | 163.983 | 161.93 | 0 |
Net Change in Cash | -35.994 | -199.047 | -163.445 | 104.568 | -21.578 |
Capital Expenditures | -0.026 | -0.026 | -0.026 | -0.022 | -0.015 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Access Industries, Inc. | Corporation | 14.8658 | 12929322 | 1475454 | 2023-10-20 | LOW |
RA Capital Management, LP | Hedge Fund | 8.9795 | 7809852 | 769230 | 2023-06-30 | LOW |
Atlas Venture | Venture Capital | 8.7479 | 7608394 | 0 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 7.0902 | 6166598 | 566826 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.9163 | 4275929 | 1143948 | 2023-06-30 | LOW |
Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 4.6431 | 4038281 | 652697 | 2023-06-30 | LOW |
Braidwell LP | Hedge Fund | 3.8653 | 3361813 | 201918 | 2023-06-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.8567 | 3354326 | 1097535 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.7199 | 3235332 | 1168668 | 2023-06-30 | LOW |
Viking Global Investors LP | Investment Advisor/Hedge Fund | 2.9418 | 2558563 | 1000000 | 2023-06-30 | MED |
Canaan Partners | Venture Capital | 2.8647 | 2491561 | -56842 | 2023-09-30 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 2.8083 | 2442500 | 1702500 | 2023-06-30 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 2.6946 | 2343567 | 155187 | 2023-06-30 | MED |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.6353 | 2292007 | 640234 | 2023-06-30 | LOW |
Nicholas Investment Partners, L.P. | Investment Advisor/Hedge Fund | 2.5722 | 2237111 | 633721 | 2023-06-30 | MED |
Blackman (Samuel C) | Individual Investor | 2.5713 | 2236319 | 1956 | 2023-08-17 | LOW |
Polar Capital LLP | Investment Advisor/Hedge Fund | 2.0404 | 1774615 | 375067 | 2023-06-30 | LOW |
Fidelity Institutional Asset Management | Investment Advisor | 1.602 | 1393305 | -1579106 | 2023-06-30 | LOW |
Deerfield Management Company, L.P. | Hedge Fund | 1.4602 | 1269992 | 1269992 | 2023-06-30 | MED |
Bender (Jeremy) | Individual Investor | 1.4572 | 1267372 | 5316 | 2023-08-17 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Day One Biopharmaceuticals Company profile
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.Industry: | Biotechnology & Medical Research (NEC) |
2000 Sierra Point Parkway, Suite 501
BRISBANE
CALIFORNIA 94005
US
Income Statement
- Annual
- Quarterly
News

A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023
XAU/USD Latest: Gold advances as weaker data weighs on US yields
Gold moves higher as softer economic data weighs on US yields and the dollar
13:43, 17 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com